TITLE:
Role of Urokinase-Type Plasminogen Activator Receptors as an Early Detector for Treatment Outcome in Adult Acute Myeloid Leukemia in Egyptian Patients
AUTHORS:
Hanan R. Nassar, Eman Z. Kandeel, Laila A. E. Hegazy, Amany M. Helal, Tarek Darwish, Soad A. Eltokhy
KEYWORDS:
AML, Plasminogen, Survival, uPAR, CD87
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.6 No.11,
October
14,
2015
ABSTRACT: Background: The urokinase-type plasminogen activator system which consists
of a proteinase (the urokinase-type plasminogen activator, uPA), a receptor (the
urokinase-type plasminogen activator receptor uPAR or CD87) and inhibitors
(PAI1) is enriched in several types of tumors and involved in proteolysis, cell
migration and invasion. High expression of uPA and uPAR is associated with an
increased relapse rate and shorter survival in breast cancer and colorectal
carcinomas. Aims: This study shed light on the expression of uPAR in adult
acute myeloid leukemia (AML) and its prognostic relevance. Methods: Peripheral blood
and bone marrow samples are obtained from 54 newly diagnosed AML adult
patients, 20 healthy controls stained with anti CD87 and estimated on flow
cytometry. Results: CD87 expression was heterogeneous in different FAB subtypes
of AML with high expression in monocytic leukemia (M4/M5) (P value 0.001). High
expression of CD87 was associated with shorter survival and poor response to therapy
(P = 0.028, 0.002 respectively). The most discriminating cut off value of CD87 expression
was 20%, patients with less than 20% expression had 4.6 times better treatment
outcome than those with more than or equal to 20%. On the multivariate
analysis, CD87 was the most significant single variable that affect treatment
outcome compared to total leucocytic count, hemoglobin level, platelets count,
cytogenetic and FLT expression. Summary/Conclusion: High CD87 expression is an
independent prognostic parameter associated with poor response and shorter
overall survival in adult AML patients.